Longterm management of Polycystic Ovarian Syndrome (PCOS)

[1]  R. Arens,et al.  Sleep and cardiometabolic function in obese adolescent girls with polycystic ovary syndrome. , 2012, Sleep Medicine.

[2]  A. D'Angelo,et al.  Effects of 1‐year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes , 2012, Journal of clinical pharmacy and therapeutics.

[3]  D. Glintborg,et al.  Age Associated Differences in Prevalence of Individual Rotterdam Criteria and Metabolic Risk Factors During Reproductive Age in 446 Caucasian Women with Polycystic Ovary Syndrome , 2012, Hormone and Metabolic Research.

[4]  R. Lobo,et al.  A 20-Year Follow-up of Young Women With Polycystic Ovary Syndrome , 2012, Obstetrics and gynecology.

[5]  D. Cramer.  The epidemiology of endometrial and ovarian cancer. , 2012, Hematology/oncology clinics of North America.

[6]  K. Gadde,et al.  Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study , 2011, The American journal of clinical nutrition.

[7]  G. Mullin,et al.  Nutraceutical supplements for weight loss: a systematic review. , 2011, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[8]  Morton B. Brown,et al.  The effect of increasing obesity on the response to and outcome of assisted reproductive technology: a national study. , 2011, Fertility and sterility.

[9]  J. DeLany,et al.  Abstract A16: Longitudinal evaluation of cancer-associated biomarkers before and after weight loss: Implications for cancer risk reduction , 2011 .

[10]  Lauren A Wise,et al.  General and abdominal obesity and risk of death among black women. , 2011, The New England journal of medicine.

[11]  S. Reis,et al.  Timing of hormone therapy, type of menopause, and coronary disease in women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation , 2011, Menopause.

[12]  Carson C. Chow,et al.  Quantification of the effect of energy imbalance on bodyweight , 2011, The Lancet.

[13]  D. Weisenburger,et al.  Risk factors for non‐Hodgkin lymphoma subtypes defined by histology and t(14;18) in a population‐based case‐control study , 2011, International journal of cancer.

[14]  A. Kunselman,et al.  Evidence for increased cardiovascular events in the fathers but not mothers of women with polycystic ovary syndrome. , 2011, Human reproduction.

[15]  L. Moran,et al.  Lifestyle changes in women with polycystic ovary syndrome. , 2011, The Cochrane database of systematic reviews.

[16]  C. la Vecchia,et al.  Metabolic syndrome and endometrial cancer risk. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  T. Hickey,et al.  PCOS Forum: research in polycystic ovary syndrome today and tomorrow , 2011, Clinical endocrinology.

[18]  J. DeLany,et al.  Longitudinal evaluation of cancer-associated biomarkers before and after weight loss in RENEW study participants: implications for cancer risk reduction. , 2011, Gynecologic oncology.

[19]  W. Dodson,et al.  The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study. , 2011, Fertility and sterility.

[20]  A. Dokras,et al.  Increased Risk for Abnormal Depression Scores in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis , 2011, Obstetrics and gynecology.

[21]  C. Lewis,et al.  Polycystic Ovary Syndrome and Risk for Long-Term Diabetes and Dyslipidemia , 2011, Obstetrics and gynecology.

[22]  A. Coomarasamy,et al.  Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. , 2010, American journal of obstetrics and gynecology.

[23]  F. Giallauria,et al.  Six weeks of structured exercise training and hypocaloric diet increases the probability of ovulation after clomiphene citrate in overweight and obese patients with polycystic ovary syndrome: a randomized controlled trial. , 2010, Human reproduction.

[24]  T. Wadden,et al.  Weight and Metabolic Outcomes After 2 Years on a Low-Carbohydrate Versus Low-Fat Diet , 2010 .

[25]  K. Hemminki,et al.  Risk of Cancer Following Hospitalization for Type 2 Diabetes , 2010, The oncologist.

[26]  R. Norman,et al.  Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. , 2010, The Journal of clinical endocrinology and metabolism.

[27]  M. Ludgate,et al.  Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. , 2009, The Journal of clinical endocrinology and metabolism.

[28]  L. Moran,et al.  Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. , 2009, Fertility and sterility.

[29]  Zoe Ann Brown,et al.  The phenotype of polycystic ovary syndrome ameliorates with aging. , 2009, Fertility and sterility.

[30]  P. Arck,et al.  Disturbed stress responses in women with polycystic ovary syndrome , 2009, Psychoneuroendocrinology.

[31]  E. Stener-Victorin,et al.  Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth? , 2008, American journal of physiology. Endocrinology and metabolism.

[32]  F. Giallauria,et al.  Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot study. , 2008, Human reproduction.

[33]  N. Johnson,et al.  Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. , 2007, Human reproduction.

[34]  W. Dodson,et al.  The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. , 2007, American journal of obstetrics and gynecology.

[35]  Huiman X Barnhart,et al.  Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. , 2007, The New England journal of medicine.

[36]  T. Wilkin,et al.  The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome , 2006, BJOG : an international journal of obstetrics and gynaecology.

[37]  J. Glanville,et al.  Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. , 2006, Human reproduction.

[38]  J. L. San Millán,et al.  The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. , 2005, The Journal of clinical endocrinology and metabolism.

[39]  C. Glueck,et al.  Obesity and extreme obesity, manifest by ages 20-24 years, continuing through 32-41 years in women, should alert physicians to the diagnostic likelihood of polycystic ovary syndrome as a reversible underlying endocrinopathy. , 2005, European journal of obstetrics, gynecology, and reproductive biology.

[40]  A. Kunselman,et al.  Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. , 2005, The Journal of clinical endocrinology and metabolism.

[41]  J. Lekakis,et al.  Metformin administration improves endothelial function in women with polycystic ovary syndrome. , 2005, European journal of endocrinology.

[42]  S. Fowler,et al.  The Effect of Metformin and Intensive Lifestyle Intervention on the Metabolic Syndrome: The Diabetes Prevention Program Randomized Trial , 2005, Annals of Internal Medicine.

[43]  S. Fowler,et al.  Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. , 2005, Diabetes.

[44]  H. S. Park,et al.  Greater beneficial effects of visceral fat reduction compared with subcutaneous fat reduction on parameters of the metabolic syndrome: a study of weight reduction programmes in subjects with visceral and subcutaneous obesity , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[45]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[46]  A. Ruokonen,et al.  Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. , 2003, The Journal of clinical endocrinology and metabolism.

[47]  P. Crosignani,et al.  Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. , 2003, Human reproduction.

[48]  Richard S Legro,et al.  Polycystic ovary syndrome and cardiovascular disease: a premature association? , 2003, Endocrine reviews.

[49]  T. Buchanan,et al.  Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. , 2002, Diabetes.

[50]  A. Kunselman,et al.  Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. , 2001, The American journal of medicine.

[51]  J. Manson,et al.  Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. , 2001, JAMA.

[52]  M. Davies,et al.  Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. , 2001, Human reproduction.

[53]  L. Niskanen,et al.  Relationship of the metabolic syndrome and obesity to polycystic ovary syndrome: a controlled, population-based study. , 2001, American journal of obstetrics and gynecology.

[54]  L. Kuller,et al.  Evidence for Association Between Polycystic Ovary Syndrome and Premature Carotid Atherosclerosis in Middle-Aged Women , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[55]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[56]  R. Norman,et al.  Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. , 1998, Human reproduction.

[57]  M. Hollmann,et al.  Effects of weight loss on the hormonal profile in obese, infertile women. , 1996, Human reproduction.

[58]  C. Galletly,et al.  Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. , 1995, Human reproduction.

[59]  S. Franks,et al.  Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. , 1992, Clinical endocrinology.

[60]  J. Annegers,et al.  Chronic Anovulation Syndrome and Associated Neoplasia , 1983, Obstetrics and gynecology.

[61]  Enrico Carmina,et al.  Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. , 2012, Fertility and sterility.

[62]  A. Powell.  Two-year sustained weight loss and metabolic benefits with controlled-release Phentermine/Topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study , 2012 .

[63]  B. Zhang,et al.  Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3 , 2011, Nature Genetics.

[64]  R. Shephard.  Body-Mass Index and Mortality among 1.46 Million White Adults , 2011 .

[65]  S. Bhattacharya,et al.  Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. , 2009, Reproductive biomedicine online.

[66]  D. Ehrmann,et al.  Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. , 2006, The Journal of clinical endocrinology and metabolism.

[67]  M. Cavaghan,et al.  Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. , 1999, Diabetes care.

[68]  W. Dodson,et al.  Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. , 1999, The Journal of clinical endocrinology and metabolism.

[69]  K. Birkeland,et al.  Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. , 1994, Metabolism: clinical and experimental.

[70]  T. Key,et al.  Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. , 1998, The Journal of clinical endocrinology and metabolism.